Spex Capital
VC Fund
London, United Kingdom
Spex Capital is a digital health and med-tech investment management firm specialised in advancing disruptive early-stage ventures to deliver breakthroughs in healthcare systems globally. We identify, support, and invest in early-stage digital health companies, to commercialise and scale within the NHS and other healthcare delivery systems.Founded in 2021 by Claudio D'Angelo, we are headquartered in London and benefit from a special NHS partnership, via DH.L & MedCity and a global healthcare ecosystem via partnerships and relationships with embassies, chambers of commerce, trade bodies, accelerators & incubators, universities, hospitals, payors and healthcare systems across all continents to source the highest caliber technologies worldwide.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Spex Capital invests in
Stages Spex Capital invests in
Countries Spex Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $400k–$2.1M
Investment Focus
Industry
- Health Care 5 (63%)
- Medical 3 (38%)
- Apps 2 (25%)
- Software 2 (25%)
- SaaS 1 (13%)
Stage
- Seed 5 (63%)
- Pre-Seed 1 (13%)
- Series A 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Claudio D'Angelo
Founder and CEO
|
Founder and CEO | Total investments: 1 | Find email | |
|
Filippo Falaschi
Investor
|
Investor | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Knok is an app-based healthcare platform offering patients a holistic solution for their health through a combination of AI chatbots, video calls, face to face appointments at home, and integration with hospitals in one single application. This solution is convenient for the patient and efficient for the health system: the AI chatbot helps patientsself-assess their condition and directs the patient within the app to a video appointment or a face to face appointment. If the issue is serious enough, knock will direct the patient to the hospital. | $2M / Seed / Nov 02, 2020 | ||
| Skin Analytics build a digital history of your skin so that you and your doctor can measure, track and ultimately understand your skin. Meaning you have the tools to take control and ultimately improve your skin health.Their patent-pending algorithms measure how the skin is changing from smartphone images to identify, inform and evaluatetreatment options across a range of consumer health and clinical skin conditions.Which means they build digital platforms that personalise skin health so people can control their skin health rather than be controlled by it.They’re focused on delivering a series of skin health products over the next 3 years ranging from consumer to clinical. | $5.2M / Series A / Sep 08, 2020 | ||
| Log my Care is a care management system for social care providers. | $754.8K / Seed / Jun 02, 2020 | ||
| MediShout is a digital platform to improve operational efficiencies, so healthcare staff can focus on patient care. MediShout brings calmness to chaotic wards and turns hospitals into smart and automated buildings. Our technology connects staff, systems, machines, and work-flow; thus improving efficiency and care. Our cloud-based technologyconnects people, Helpdesks, smartphones, tablets, IT systems, and RFID tagging. | Pre-Seed / May 28, 2020 | ||
| Firza is a medical company modernizing healthcare using technology-enabled, bespoke workforce solutions. The company also specializes in robotic process automation, artificial intelligence, and technology backed workforce solutions for Primary Health Care. They providing real-world commercial and clinical solutions to the NHS, GP Practices,Pharmacies, and healthcare organizations across the country.Firza's experience of working in General Practice enables them to mobilize quickly and respond with viable solutions that suit the individual needs of the practice team. They deliver technology and digital services for the modern-day General Practice.Firza was founded in 2014 and is headquartered in London, England, United Kingdom. | Seed / May 27, 2020 | ||
| LiveSmart provides health assessments and reacted quickly to the new situation. The team sourced and supplied antibody tests via their well-established platform; supporting both small businesses and large corporate clients. | $400K / Seed / May 26, 2020 | ||
| LiveSmart provides health assessments and reacted quickly to the new situation. The team sourced and supplied antibody tests via their well-established platform; supporting both small businesses and large corporate clients. | Seed / Jan 20, 2019 | ||
| Skin Analytics build a digital history of your skin so that you and your doctor can measure, track and ultimately understand your skin. Meaning you have the tools to take control and ultimately improve your skin health.Their patent-pending algorithms measure how the skin is changing from smartphone images to identify, inform and evaluatetreatment options across a range of consumer health and clinical skin conditions.Which means they build digital platforms that personalise skin health so people can control their skin health rather than be controlled by it.They’re focused on delivering a series of skin health products over the next 3 years ranging from consumer to clinical. | $2.1M / Seed / Jan 20, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Spex Capital invest in?
Spex Capital invests primarily in Health Care, Medical and Apps startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Spex Capital's check size?
Spex Capital typically joins rounds of $400k–$2.1M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Spex Capital participates in.
How do I contact Spex Capital?
Public channels for Spex Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Spex Capital?
The team at Spex Capital includes Claudio D'Angelo (Founder and CEO) and Filippo Falaschi (Investor). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
